bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
=== Aquaculture === In 2013, Whole Foods began selling farm-raised arapaima in the United States as a cheaper alternative to halibut or Chilean sea bass. In Thailand, the only legal breeding farm is located in Tambon Phrong Maduea, Amphoe Mueang Nakhon Pathom, Nakhon Pathom Province. This has been approved by both the Department of Fisheries and CITES since early 2018, and has been exporting them worldwide as an aquarium fish.
genetic information stored in the sequence of DNA molecules a "messenger" RNA molecule to carry the instructions for making one protein to the cytoplasm adaptor molecules ("they might contain nucleotides") to match short sequences of nucleotides in the RNA messenger molecules to specific amino acids ribonucleic-protein complexes that catalyse the assembly of amino acids into proteins according to the messenger RNA The adaptor molecules were eventually shown to be tRNAs and the catalytic "ribonucleic-protein complexes" became known as ribosomes. An important step was the realisation by Crick and Brenner on 15 April 1960 during a conversation with François Jacob that messenger RNA was not the same thing as ribosomal RNA. Later that summer, Brenner, Jacob, and Matthew Meselson conducted an experiment which was the first to prove the existence of messenger RNA. None of this, however, answered the fundamental theoretical question of the exact nature of the genetic code. In his 1958 article, Crick speculated, as had others, that a triplet of nucleotides could code for an amino acid. Such a code might be "degenerate", with 4×4×4=64 possible triplets of the four nucleotide subunits while there were only 20 amino acids. Some amino acids might have multiple triplet codes. Crick also explored other codes in which, for various reasons, only some of the triplets were used, "magically" producing just the 20 needed combinations. Experimental results were needed; theory alone could not decide the nature of the code.
Acebutolol, sold under the brand names Sectral among others, is a beta blocker for the treatment of hypertension and arrhythmias. Acebutolol is a cardioselective beta-1 blocker and has intrinsic sympathetic activity. It is commonly used in the treatment of angina. It was patented in 1967 and approved for medical use in 1973.
== Bismuth-213 == Bismuth-213 (213Bi) has a half-life of 45.6 minutes and decays mainly by beta emission to polonium-213; with only 2.1% going via alpha emission to thallium-209; however, as the polonium instantly decays by alpha, one alpha particle is emitted per atom. The amounts needed for medical use are always produced through its decay chain (the neptunium series) from either thorium-229 (limited supply due to the long life of that isotope) or actinium-225, which can be produced directly from radium-226, for example by bombardment with bremsstrahlung photons from a linear particle accelerator, knocking out a neutron and through beta decay giving actinium-225. In 1997, an antibody conjugate with 213Bi was used to treat patients with leukemia, and this isotope has otherwise been used in targeted alpha therapy (TAT) to treat a variety of cancers. Bismuth-213 is also produced in the decay of uranium-233, the fuel bred by thorium reactors, but as mentioned this goes through the long-lived thorium-229, so the production rates from each reactor will not be large.
The first performance in Los Angeles in 1954 was introduced with a tribute to Thomas from Aldous Huxley. Thomas spent the last nine or ten days of his third tour in New York mostly in the company of Reitell, with whom he had an affair. During this time, Thomas fractured his arm falling down a flight of stairs when drunk. Reitell's doctor, Milton Feltenstein, put his arm in plaster and treated him for gout and gastritis. After returning home, Thomas worked on Under Milk Wood in Laugharne. Aeronwy, his daughter, noticed that his health had "visibly deteriorated...I could hear his racking cough. Every morning he had a prolonged coughing attack...The coughing was nothing new but it seemed worse than before." She also noted that the blackouts that Thomas was experiencing were "a constant source of comment" amongst his Laugharne friends. Thomas sent the original manuscript to Douglas Cleverdon on 15 October 1953. It was copied and returned to Thomas, who lost it in a pub in London and required a duplicate to take to America. Thomas flew to the States on 19 October 1953 for what would be his final tour. He died in New York before the BBC could record Under Milk Wood. Richard Burton starred in the first broadcast in 1954, and was joined by Elizabeth Taylor in a subsequent film. In 1954, the play won the Prix Italia for literary or dramatic programmes.
Sources: en.wikipedia.org
== Human proteins containing this domain == SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC6A5, SLC6A6, SLC6A7, SLC6A8, SLC6A9, SLC6A11, SLC6A12, SLC6A13, SLC6A14, SLC6A15, SLC6A16, SLC6A17, SLC6A18, SLC6A19, SLC6A20
Source: Tendon cells originate during fetal development from mesenchymal stem cells, which differentiate into tenocytes and fibroblasts. In adults, tendon cells maintain the integrity of the tendon through continuous remodeling. The regeneration capacity of tendon cells is limited, which can make healing after injury slower compared to other tissues. Research has identified several molecular players that govern tendon cell differentiation and development. These include transcription factors (e.g., Scleraxis (Scx), Sox9) and signaling pathways (e.g., BMPs, Wnt, Fgf), which regulate tendon precursor cells and their transition into mature tenocytes. However, the full spectrum of molecular regulators remains largely unknown, and understanding these molecular networks is a key goal for future research.
== Diagnosis == Genetic testing for the m.3243A>G mutation in mitochondrial DNA is commonly used to isolate the diagnosis of MELAS syndrome from other mitochondrial disorders. This mutation is an adenine to guanine point mutation at base pair 3,243 in the mitochondrial genome. A minimum amount of mtDNA must be mutated to generate the MELAS phenotype, known as the "threshold effect". Due to mitochondrial heteroplasmy, urine and blood testing is preferable to blood alone. PCR and ARMS-PCR are commonly used, reliable, rapid, and cost-effective techniques for the diagnosis of MELAS. Magnetic-resonance imaging (MRI) is a common imaging test used to identify the presence of stroke-like lesions. These lesions are multifocal infarct-like areas of cortical edema in different stages of ischemic evolution, yet do not commonly conform to any known vascular territory, distinguishing them from a stroke. Initial lesions often occur in the occipital or parietal lobes with eventual involvement of the cerebellum, cerebral cortex, basal ganglia, and thalamus. The occipital lobe is thought to be a region prone to stroke-like lesions due to the high energy requirements of the visual cortex. Lactate levels are often elevated in serum and cerebrospinal fluid. Magnetic resonance spectroscopy (MRS) may show an elevated lactate peak in affected and even unaffected brain areas. Muscle biopsy shows ragged red fibers. However, genetic evaluation should be done first, which eliminates the need for muscle biopsy in most cases. Diagnosis may be molecular or clinical:
PET scans are increasingly read alongside CT or MRI scans, with the combination (co-registration) giving both anatomic and metabolic information (i.e., what the structure is, and what it is doing biochemically). Because PET imaging is most useful in combination with anatomical imaging, such as CT, modern PET scanners are now available with integrated high-end multi-detector-row CT scanners (PET–CT). Because the two scans can be performed in immediate sequence during the same session, with the patient not changing position between the two types of scans, the two sets of images are more precisely registered, so that areas of abnormality on the PET imaging can be more perfectly correlated with anatomy on the CT images. This is very useful in showing detailed views of moving organs or structures with higher anatomical variation, which is more common outside the brain. At the Jülich Institute of Neurosciences and Biophysics, the world's largest PET–MRI device began operation in April 2009. A 9.4-tesla magnetic resonance tomograph (MRT) combined with a PET. Presently, only the head and brain can be imaged at these high magnetic field strengths. For brain imaging, registration of CT, MRI and PET scans may be accomplished without the need for an integrated PET–CT or PET–MRI scanner by using a device known as the N-localizer.
=== Pennate muscles and aponeuroses === Pennate muscles, in which the muscle fibers are oriented at an angle to the line of action, typically have two aponeuroses. Muscle fibers connect one to the other, and each aponeurosis thins into a tendon which attaches to bone at the origin or insertion site.
Sources: en.wikipedia.org
This follows an exchange in the House during PMQs when Starmer, answering a question from the leader of the opposition, Kemi Badenoch, said that "two of her predecessors had convictions for breaking the Covid rules". Although the former Conservative prime ministers, Johnson and Rishi Sunak had received fixed penalty notices for breaking Covid-19 regulations, neither had any criminal convictions. Scottish Finance Secretary Shona Robison delivers the 2024 budget, which includes planned changes to taxation and a pledge to scrap the two child benefit cap in Scotland. Welsh Conservative leader Andrew RT Davies tells BBC News Wales there has been "plotting" among Conservative Senedd members to oust him since April. Secretary of State for Northern Ireland Hilary Benn begins the process of repealing the controversial Legacy Act. 27-year-old Sam Smith is announced as the new leader of Nottinghamshire County Council. Karen Kilgour, leader of Newcastle City Council, faces a vote of no confidence. 5 December – Starmer delivers a major speech in which he sets out six objectives which he says "give the British people the power to hold our feet to the fire"; the objectives cover the economy, housebuilding, the NHS, policing, pre-school education and green energy. Questions are raised over whether Henry Tufnell, the MP for Mid and South Pembrokeshire, gave his parents advanced knowledge of plans to change inheritance tax rules after they transferred ownership of farm land to one of their sons days before the budget.
Automation of synthesis has three main benefits: increased efficiency, quality (yields and purity), security, and safety, all resulting from decreased human involvement. As machines work faster than humans and are not prone to human error, throughput and reproducibility increases. Additionally, as humans spend less time in the lab exposure to dangerous chemicals is significantly decreased. This allows chemists additional time for theory and collaborative discussions. Additional benefits include: multitasking, performing tasks beyond the scope of human precision or ability, exhaustive analysis, etc.
Equine chorionic gonadotropin Gonadotropin preparations Human placental lactogen Pregnancy hormones Triple test, a screening test in pregnancy The Weight-Loss Cure "They" Don't Want You to Know About, a book written by Kevin Trudeau Chorionic+Gonadotropin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "History of pregnancy test". U.S. National Institutes of Health. Archived from the original on 2011-01-13. Retrieved 2011-01-10.
==== Manufacturing process ==== The process for making the americium used in the buttons on ionization-type smoke detectors begins with americium dioxide. The 241AmO2 is thoroughly mixed with gold, shaped into a briquette, and fused by pressure and heat at over 1,470 °F (800 °C). A backing of silver and a front covering of gold (or an alloy of gold or palladium) are applied to the briquette and sealed by hot forging. The briquette is then processed through several stages of cold rolling to achieve the desired thickness and levels of radiation emission. The final thickness is about 0.008 inches (0.20 mm), with the gold cover representing about one percent of the thickness. The resulting foil strip, which is about 0.8 inches (20 mm) wide, is cut into sections 39 inches (1 m) long. The sources are punched out of the foil strip. Each disc, about 0.2 inches (5.1 mm) in diameter, is mounted in a metal holder, usually made of aluminium. The holder is the housing, which is the majority of what is seen on the button. The thin rim on the holder is rolled over to completely seal the cut edge around the disc.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.